Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 187004 CL in Patients With Type 2 Diabetes Mellitus (Randomized, Double-blind Placebo-controlled Within Dose Groups)
Latest Information Update: 02 Jan 2023
At a glance
- Drugs BI 187004 CL (Primary)
- Indications Obesity; Overweight; Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 01 Dec 2022 Results (n=34) assessing safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 187004 After Multiple Dosing Over 14 Days in male and female patients with type 2 diabetes and overweight or obesity published in the Experimental and Clinical Endocrinology and Diabetes
- 08 Jan 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 18 Jun 2013 New trial record